M

Mabion SA
WSE:MAB

Watchlist Manager
Mabion SA
WSE:MAB
Watchlist
Price: 8.24 PLN -0.48% Market Closed
Market Cap: zł133.2m

Operating Margin

-379.1%
Current
Declining
by 317.4%
vs 3-y average of -61.7%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-379.1%
=
Operating Income
zł-56.2m
/
Revenue
zł14.8m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-379.1%
=
Operating Income
zł-56.2m
/
Revenue
zł14.8m

Peer Comparison

Country Company Market Cap Operating
Margin
PL
Mabion SA
WSE:MAB
133.8m PLN
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.1B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
167.9B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.8B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Lower than 94% of companies in Poland
Percentile
6th
Based on 835 companies
6th percentile
-379.1%
Low
-10 083 900% — -1.5%
Typical Range
-1.5% — 11.7%
High
11.7% — 195 905.3%
Distribution Statistics
Poland
Min -10 083 900%
30th Percentile -1.5%
Median 5.4%
70th Percentile 11.7%
Max 195 905.3%

Mabion SA
Glance View

Market Cap
133.2m PLN
Industry
Biotechnology

Mabion SA is a biotechnology company, which engages in the development and manufacture of biotech drugs. The company is headquartered in Konstantynow Lodzki, Woj. Lodzkie and currently employs 213 full-time employees. The company went IPO on 2010-08-10. Mabion SA was founded by four pharmaceutical companies, including Celon Pharma Ltd, Polfarmex Co, Genexo Ltd and IBSS Biomed Co, as well as two companies focused on research and development in biotechnology field, including BioCentrum Ltd and Biotech Consulting Ltd. The firm specializes in the humanized monoclonal antibodies (mAbs) technology, a new generation of biotechnological drugs. The company focuses on oncology drugs used to treat blood cancer, lymphomas and leukemias, rheumatoid arthrisis, as well as breast cancer. The company operates its own Research and Development Center in the Special Economical Zone in Lodz, Poland.

MAB Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-379.1%
=
Operating Income
zł-56.2m
/
Revenue
zł14.8m
What is Mabion SA's current Operating Margin?

The current Operating Margin for Mabion SA is -379.1%, which is below its 3-year median of -61.7%.

How has Operating Margin changed over time?

Over the last 3 years, Mabion SA’s Operating Margin has decreased from 16.4% to -379.1%. During this period, it reached a low of -537.7% on Jun 30, 2025 and a high of 47.9% on Sep 30, 2023.

Back to Top